Amid drug price worries, earnings to test U.S. pharma, biotech shares
April 23, 2018 at 16:36 PM EDT
NEW YORK, April 23 (Reuters) - Major U.S. pharmaceutical and biotechnology companies, whose shares have been laggards even in a sluggish market, face a litmus test in the corporate earnings season as investors already gun-shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses.
